您的位置>>首页 > 师资队伍
师资队伍
葛玉斌
基本情况
姓名: 葛玉斌
性别:
职称: 教授
是否博导:
最高学历: 研究生
最高学位: 博士
电话:
Email:
详细情况
所研究方向: 主要从事儿童急性白血病及其它肿瘤(如胰腺癌、神经母细胞瘤)的转化医学研究。研究唐氏综合症急性髓细胞白血病患者具有高治愈率的分子机理;转录因子在急性髓细胞白血病发生及治疗中的作用;组蛋白去乙酰化酶抑制剂、Bcl-2抑制剂等小分子选择性抑制剂在急性髓细胞白血病、胰腺癌和神经母细胞瘤治疗中的作用及其机制。
教育经历: 1995/09 – 1998/06,吉林大学,生物化学与分子生物学,博士
1992/09 – 1995/06,吉林大学,生物化学与分子生物学,硕士
1988/09 – 1992/06,吉林大学,生物化学与分子生物学,学士
工作经历: 2010-现在 吉林大学生命科学学院, 教授
2008-2010 吉林大学生命科学学院, 客座教授
2007-2010 美国韦恩州立大学医学院 Assistant Professor (Tenure-Track)
2004-2007 美国韦恩州立大学医学院 Assistant Professor (research)
2002-2004 美国韦恩州立大学医学院 Research Associate
1999-2002 美国韦恩州立大学医学院 博士后
1998-1999 澳大利亚昆士兰大学 博士后
1997-2002 吉林大学生命科学学院 讲师
1995-1997 吉林大学生命科学学院 助教
科研项目: 负责或参与十余项国内外科研项目。
1. 国家自然科学基金青年基金 (31100542): 通过阻断Hsp90/Cdc37相互作用抑制
胰腺癌肿瘤生长的新型Hsp90抑制剂的研究, 20万, 2012.1-2014.12, 参与。
2. 国家自然科学基金面上项目 (31271477): CHK1介导组蛋白去乙酰化酶抑制剂
协同化疗药物杀伤AML细胞的机理研究, 80万,2013.1-2016.12,负责人。
3. 国家自然科学基金面上项目 (31471295): Bcl-2选择性抑制剂ABT-199抗急性
髓细胞白血病的机制研究, 85万, 2015.1-2018.12,负责人。
4. 国家自然科学基金面上项目(31671438):多靶点干预:CUDC-907协同ABT-
199抑制AML的分子机制,25万,2017.1-2018.12,负责人。
学术论文: 共发表期刊论文95篇,其中90篇为SCI论文。

近3年发表的SCI论文:

1. Ning C, Liang M, Wang G, Edwards H, Polin S, Dyson G, Mohammad RM, Azmi AS, Zhao L, and Ge Y. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic Cancer. Oncotarget. 2017; 8:44925-44311.

2. Taub JW, Berman JN, Hitzler JH, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, and Gamis AS. Improvement in treatment outcome and identification of a new prognostic parameter in myeloid leukemia of Down syndrome (ML-DS): results of the children’s oncology group (COG) phase III AAML0431 trial. Blood. 2017; 129(25):3304-3313. (ASH Clinical News June 2017 Paper Spotlight: Predicting survival outcomes for children with Down syndrome and AML or MDS; Inside Blood Commentary: Shand JC. Looking up for AML in Down syndrome. Blood 129: 3273-3274, 2017)

3. Liu S, Ge Y, Edwards H, Ren Q, Jiang Y, Quan C, and Wang G. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine. Oncol Rep. 2017; 37:3377-3386.

4. Luedtuke D, Niu X, Pan Y, Zhao J, Liu S, Edwards H, Wang G, Lin H, Taub JW, and Ge Y. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor Venetoclax in AML cells. Signal Transduction and Targeted Therapy. 2017; 2:e17012.

5. Ma J, Li X, Su Y, Zhao J, Luedtke D, Epshteyn V, Edwards H, Wang G, Wang Z, Chu R, Taub JW, Lin H, Wang Y, and Ge Y. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. Sci Rep. 2017; 7:41950.

6. Zhao J, Xie C, Edwards H, Wang G, Taub JW, and Ge Y. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells. Oncotarget. 2017; 8:6319-6329.

7. Liao Y, Niu X, Chen B, Edwards H, Xu L, Xie C, Lin H, Polin LA, Taub JW, Ge Y, Qin Z.Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells. J Med Chem. 2016; 59:7974-7990.

8. Ahsan S, Ge Y, Tainsky MA.Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Oncotarget. 2016; 7:57171-57185.

9. Zhao J, Niu X, Li X, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Ge Y.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Oncotarget. 2016; 7:34785-34799.

10. Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, Caldwell JT, Xiang S, Zhang X, Chu R, Wang ZJ, Lin H, Taub JW, Ge Y.Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clin Cancer Res. 2016; 22:4440-4451.

11. Shaham L, Vendarmini E, Ge Y, Goren Y, Tijssen M, Birger Y, McNulty M, Geron I, Schwartzman O, Goldberg L, Chou ST, Pitman H, Weiss MJ, Michaeli S, Sredni B, G?ttgens B, Crispino J, Taub JW, and Izraeli S. MiR-486-5p is an oncomiR in the myeloid leukemias of Down Syndrome. Blood. 2015;125:1292-301.

12. Xie C, Edwards, Caldwell JT, Wang G, Taub JW, and Ge Y. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol. 2015; 9: 409-421.

13. Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W, Taub JW, Zhao L, and Ge Y. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Lett. 2015; 356: 656-668.

14. Hanmod S, Wang G, Edwards H, Buck SA, Ge Y, Taub JW, and Wang Z. Targeting histone deacetylases (HDACs) and wee1 for treating high-risk neuroblastoma. Pediatr Blood Cancer. 2015; 62: 52-59.

15. Wang G, Chen S, Edwards H, Cui X, Cui L, and Ge Y. Combination of chloroquine and obatoclax results in synergistic cytotoxicity against pancreatic cancer cells. Oncol Rep. 2014; 32: 2789-94.

16. Caldwell JT, Ge Y, and Taub JW. Prognosis and management of acute myeloid leukemia in patients with Down syndrome. Expert Rev Hematology. 2014; 7: 831-840.

17. Qi W, Xie C, Li C, Caldwell JT, Edwards H, Taub JW, Wang Y, Lin H, and Ge Y. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol. 2014; 7(1):53.

18. Niu X, Wang G, Wang Y, Caldwell JT, Edwards H, Xie C, Taub JW, Li C, Lin H, and Ge Y. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2 selective inhibitor ABT-199. Leukemia. 2014; 28:1557-1560.

19. Caldwell JT, Edwards H, Buck SA, Ge Y, and Taub JW. Targeting the wee1 Kinase for Treatment of Pediatric Down Syndrome Acute Myeloid Leukemia. Pediatr Blood Cancer. 2014; 61: 1767-1773. [Featured on the cover for the issue].

20. Chen S, Wang G, Niu X, Zhao J, Tan W, Wang H, Zhao L, and Ge Y. Combination treatment with AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett. 2014; 348: 20-28.


着作教材: 1.Xavier AC, Ge Y, Taub JW. Down syndrome and leukemia. In: Cancer in Children and Adults with Intellectual Disabilities: Current Research Aspects. Eds: Merrick J and Satgé D. Nova Science Publishers Inc. (ISBN-10: 161761856X, ISBN-13: 9781617618567). 1st Edition, March 2011.

2.Taub JW, Ge Y and Ravindranath Y. Down Syndrome and Acute Myeloid Leukemia: An Unique Genetic Sensitivity to Chemotherapy. In (Eds PJ Houghton, R. Arceci) Molecularly-Targeted Therapy for Childhood Cancer. Springer, NY (ISBN: 978-0-387-69060-5). XVIII, 109-122, 2010.
获奖情况: 1)在2003和2004年,两次获得美国国家唐氏综合症协会年度 “Charles J. Epstein Down Syndrome Research Award”奖。

2)在2007年,获得美国韦恩州立大学医学院颁发的“Faculty Research Excellence Award”。
社会兼职: Member, American Association for Cancer Research
Active member, American Society of Hematology

版权所有:吉林大学生命科学学院 2017 © 电话:+(86)-431-81969061

地址:吉林省长春市前进大街2699号生命科学楼 邮编:130012   Power by leeyc